Bekes Varmegyei Koezponti Korhaz
- Address
- lock Available on a paid plan
Respiratory and Thoracic Oncology
At Bekes Varmegyei Koezponti Korhaz in Gyula, a major share of research focuses on respiratory tract diseases and neoplasms, especially non-small cell lung cancer and related advanced lung tumors. These studies are designed to test new treatment approaches, compare them with current standards, and improve survival outcomes for people with difficult-to-treat cancers.
- Non-small cell lung cancer and advanced lung cancer
- Stage IV, metastatic, and PD-L1–positive disease
- Evaluating new cancer therapies and combinations against established care
The site’s pulmonary department supports a broad oncology portfolio, with research aimed at better disease control, longer progression-free survival, and improved overall outcomes.
Breast and Prostate Cancer Research
The clinical trial program includes extensive work in breast cancer and prostate cancer, covering both early and advanced disease. Studies are exploring new endocrine-based strategies, targeted treatments, and combination approaches to reduce recurrence and improve disease control in hormone-driven cancers.
- ER-positive, HER2-negative breast cancer
- Metastatic breast cancer and high-risk early-stage disease
- Prostate cancer, including metastatic castration-resistant and high-risk localized disease
Research at the site includes efforts to prevent recurrence, delay progression, and identify more effective options for patients whose cancer has returned or spread.
Autoimmune and Inflammatory Diseases
A strong portion of the research landscape centers on immune system diseases and chronic inflammatory conditions such as systemic lupus erythematosus, psoriatic arthritis, rheumatoid arthritis, and Sjögren’s syndrome. These trials are mainly aimed at improving symptom control, reducing disease activity, and assessing the long-term safety of newer immune-modulating treatments.
- Systemic lupus erythematosus and related systemic autoimmune disease
- Psoriatic arthritis and rheumatoid arthritis
- Sjögren’s syndrome and other immune-mediated disorders
This area reflects a broad interest in therapies that may help patients live with fewer flares, less inflammation, and better daily function.
Cardiovascular and Metabolic Medicine
The site also conducts research in cardiovascular diseases and nutritional and metabolic diseases, including heart failure, acute myocardial infarction, hyperlipidaemia, and type 2 diabetes. These studies are focused on lowering cardiovascular risk, improving heart function, and testing whether newer therapies can better support long-term prevention and treatment.
- Heart failure and inflammation-related cardiac disease
- Acute myocardial infarction and prevention of recurrent events
- Hyperlipidaemia and type 2 diabetes
Research in this field aims to reduce serious complications such as heart attack, stroke, and worsening heart failure while improving everyday disease management.
Infectious, Liver, and Surgical Care
Clinical trials at the hospital cover bacterial infections, virus diseases, and selected digestive system diseases, including chronic hepatitis B and primary biliary cholangitis. There is also work on preventing surgical infections and supporting safer care around urgent procedures.
- Chronic hepatitis B and liver-related disease
- Post-surgical infection prevention
- Bacterial pneumonia and other serious infections
These studies are intended to improve infection control, support recovery after surgery, and explore better options for chronic liver conditions with ongoing symptoms.
Additional Chronic Disease and Symptom-Focused Research
Beyond the main specialty areas, Bekes Varmegyei Koezponti Korhaz participates in trials across a wide range of chronic conditions, including chronic obstructive pulmonary disease, chronic kidney disease, pruritus, and selected mental disorders in children and adolescents. The aim is often to improve symptom relief, strengthen disease control, or assess whether new therapies can offer better everyday outcomes.
- COPD and other chronic respiratory conditions
- Chronic kidney disease and multisystem inflammatory disease
- Pruritus and symptom-driven quality-of-life research
This mix of studies shows a broad clinical research profile that extends beyond one specialty, with attention to both complex diseases and patient-reported symptoms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 18 therapeutic areas and 15 of 189 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 184 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 34 by active trials.
- 1AstraZeneca AB8active
lock +33 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB11trials
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Bekes Varmegyei Koezponti Korhaz
lock Showing 1 of 130 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus | Bristol Myers Squibb International Corporation | Phase II | Not Recruiting | May 2019 | Mar 2025 |
IMP list
lock Showing 1 of 189 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 11 | Unknown | 2018-08-24 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
